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                                             INTRODUCTION 
Diabetes mellitus is a group of disorders characterized by chronic 
hyperglycemia associated with disturbances of carbohydrate, protein, and fat 
metabolism, due to absolute or relative deficiency in insulin secretion and /or 
action. 
Diabetes causes long term damage, dysfunction and failure of various organs 
especially the eyes, kidneys, nerves, heart and blood vessels. 
There are two types of diabetes mellitus present.  
Type-I DM - These patients depend on insulin for survival. There is 
autoimmune destruction of  cells here. 
Type 2-DM - impaired beta cell function with marked increase in peripheral 
insulin resistance and increased hepatic glucose output production. 
In diabetic ketoacidosis, one of the hyperglycemic emergencies, there is 
insulin deficiency coupled with concomitant elevation of counter regulatory 
hormones. This hormonal imbalance promotes gluconeogenesis, glycolysis, 
glycogenolysis, protein breakdown and lipolysis. 
The metabolic dearrangements of patients with DKA are hyperglycemia, 
metabolic acidosis, ketosis etc. 
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There are case reports, showing non specific elevation of serum amylase and 
lipase in patients with DKA, without actual pancreatic involvement. 
The symptoms of DKA like nausea, vomiting, epigastric pain can be present in 
acute pancreatitis also. 
Elevation of serum amylase, and lipase levels in association with severe 
abdominal pain often trigger the initial diagnosis of acute pancreatitis. 
But in the presence of DKA, the patient may need CECT abdomen to diagnose 
acute pancreatitis. 
So, it was decided to undertake a cross sectional study on the elevation of 
serum amylase and lipase in patients with DKA, and its relevance to the 
presence of acute pancreatitis, in the institute of internal medicine, Rajiv 
Gandhi Government General Hospital, Chennai. 
 
 
 
 
 
8 
 
 
 
                                      AIMS AND OBJECTIVES 
1. To measure the levels of serum amylase and lipase in patients with DKA 
2. To Analyse whether elevated amylase and lipase levels can be present 
without actual pancreatic involvement in the presence of  DKA 
3. To identity the correlation between the elevation of serum amylase, lipase 
and morbidity, mortality of  DKA 
4. To identity the correlation between the elevation of serum amylase, lipase 
and variables like Na+ ,K+ ,HCo3, Ph, urea, blood, sugar, serum osmolality, 
and types of DM. 
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REVIEW OF THE LITERATURE 
DIABETIC KETO ACIDOSIS 
  Diabetic Keto acidosis remaining as a very serious medical 
condition and it leads to morbidity and mortality particularly in Patients with 
Type-1 diabetes mellitus and also in patients with type-2 diabetes mellitus to 
some extent. 
  In type 1 Diabetes mellitus, Diabetic keto acidosis can be the 
presenting manifestation at the starting itself. The presence of Type-1 
diabetes mellitus may be diagnosed after the initial symptom complex of DKA 
in some cases. 
  But the Diabetic keto acidosis occurs usually in individuals already 
diagnosed to have diabetes mellitus. 
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  Catobolic stress of trauma, surgery, infections, acute 
cerebrovascular accidents, myocardial infarctions lead to diabetic keto 
acidosis in patients with type 2 diabetes mellitus. 
  Auto immune type 1 diabetes leads to diabetic ketoacidosis when 
patient omits the insulin therapy. 
  After the introduction of insulin therapy, the mortality in DKA is 
less than 5% only. 
Diagnostic Criteria of diabetes mellitus. 
  Without regard to time since the last meal, blood glucose 
concentration 11.1(mmol/L)/200mg/dl, with symptoms of diabetes 
(or) 
plasma glucose 7.00mmol/L (126 mg/dl) after a fasting for atleast 8 hours 
(or) 
In the Laboratory certified according to AIC standards, AIC >6.5% 
11 
 
(or) 
Two hours post 75g glucose load plasma glucose >11.1 mmol/L (200mg/dl). 
  These criteria should be confirmed once again on different day if 
there is no unequivocal hyperglycemia and acute metabolic  decompensation. 
 
Diagnostic Criteria of DKA: 
  Diabetic ketoacidosis consists of biochemical triad of 
hyperglycemia, ketonemia and acidemia. Each of these features by itself can 
be caused by other metabolic conditions. Diagnosis of ketoacidosis is based on 
the characteristic clinical features and biochemical abnormality. The 
differential diagnosis includes hyper osmolar hyper glycemic  non ketotic 
coma. 
Laboratory Parameters: 
Hyper glycemia 250 mg/dl 
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Acidosis (PH-6.8-7.3) and/or serum HCO3 <15meq/L 
Ketonuria or Ketonemia 
 
 
 
Pathogenesis: 
  DKA is a medical emergency that is due to relative or absolute 
insulin deficiency along with excess of glucagon, catecholamines, cortisol and 
growth hormone. (1, 3, 4, 8-13). 
  In DKA, there is increased hepatic gluconeogenesis and renal 
glucose output combined with decreased glucose uptake in peripheral tissues 
due to insulin deficiency lead to hyperglycemia inturn leads to increased 
osmolality of extracellular fluid, (1, 3, 10-17). 
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  In type 1 diabetes mellitus there is total or relative absence of 
insulin leads to pure DKA not associated with significant hyper osmolarity. 
  The development of DKA needs both insulin deficiency and 
glucagon excess. 
  The insulin deficiency and counter regulatory hormones in excess 
lead to increased lipolysis and release of fatty acids from adipose tissues. 
  The free fatty acids are converted to beta hydroxy butyrate and 
acetoacetate by liver resulting in ketosis and metabolic acidosis (18). 
  The excessive glucose in blood leads to osmotic diuresis so loss of 
water, sodium, potassium and other electrolytes occur in DKA (6, 15-17). 
  Reactive oxygen species are produced during DKA, as DKA is one 
of the pro inflammatory state lead to oxidative stress. 
  The levels of lipid peroxidation markers, pro inflammatory 
cytokines, plaminogen activator inhibitor type 1 and C-reactive protein (CRP) 
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all are elevated in diabetic ketoacidosis, returns to normal once insulin 
therapy is started and hyper glycemia is controlled (19). 
 
PRECIPITATING FACTORS: 
  The Most common precipitating factor is omission of insulin 
particularly in type-1 diabetes mellitus in young adults, (1, 4, 8-12). 
  Infection is also one of the most common precipitating factors 
causing DKA (1, 4, 8-12). 
 
Other Causes: 
Acute Pancreatitis. 
Acute myocardial infarction. 
Acute cerebrovascular accident 
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Drugs that affect glucose metabolism like glucocorticoids, thiazides, 
dobutamine, terbutaline (10), Anti Psychotics particularly second 
generation lead to development of DKA (20). 
  Omission of insulin in type 1 diabetes, and new onset type 1 
diabetes may present themselves as DKA. 
  In children, adolescents and adults with type-2 DM, cases have 
been reported without identifiable precipitating factors. 
  In those cases, high rate of obesity, strong family history of 
diabetes, measurable pancreatic reserve, less prevalence of auto immune 
markers of B cell destruction, and ability to discontinue insulin therapy during 
follow up, are the important clinical and metabolic features (28, 29). 
  So this kind of type-2 diabetes is otherwise called with various 
names like type 1.5 diabetes, flat bush diabetes, idiopathic type-1 diabetes, 
atypical diabetes, and type 2 diabetes-ketosis prone (24, 30). 
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   Those cases  have severe deficiency of insulin secretion and their 
action, in early stage (25, 26, 29), but when they are treated with insulin 
aggressively, they become normal in due course, showing improved beta cell 
function after a few months of follow up (25, 27). 
  Around 40% of patients with type-2 DM (ketosis prone), remains 
as non-insulin dependent even after 10 years of achieving near 
normoglycemic remission showing greater recovery of basal and stimulated 
insulin secretion (24-27). 
 
 
 
DIAGNOSIS: 
History and Physical Examination 
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  In both type 1 and type 2 diabetes mellitus, the evolution of the 
acute DKA is shorter ( 24 hr). 
  The symptoms of poorly controlled diabetes like polyuria, poly 
dipsia etc. may be present for months, but the alterations in metabolic 
parameters typical of DKA develops in short period only. It is typically less 
than 24 hours. 
 Polyuria, 
 Polydipsia, 
 Weight loss 
 Vomiting 
 Abdominal Pain 
 Dehydration 
 Weakness 
18 
 
 Mental status changes 
 Coma 
  These are the classic clinical features of patients with DKA. 
 Poor Skin turgor 
 Kussmaul respiration 
 Tachy cardia 
 Hypotension 
 Alteration in mental status, 
 Ultimately coma 
  These are other physical findings present in DKA. 
  These DKA patients may have coffee ground vomiting that is 
guaiac positive. Upto 25% patients can have emesis like this. 
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  The spectrum of mental status changes are from full alertness, 
profound lethargy to coma. 
  The peripheral vasodilation leads to hypothermia. (32) They can 
be even normothermic. 
  The presence of hypothermia is one of the poor prognostic marker 
of DKA. 
  In 50-70% of DKA cases, abdominal pain may be main symptom 
mimicking an acute abdomen. (33, 34). 
  When the hyperglycemia and metabolic acidosis is corrected, the 
abdominal pain usually gets corrected. 
  Hemiparesis, hemianopsia and seizures (partial motor seizures 
more common than generalised) may be the presenting features in some 
cases. These usually resolve once metabolic parameters are corrected. 
Laboratory Findings: 
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Hyper glycemia 
Ketonemia 
Metabolic acidosis 
are the Bio chemical triad of DKA 
  Increased anion gap metabolic acidosis results from accumulation 
of ketoacids. 
  The sum of chloride and bicarbonate is subtracted from the sum 
of sodium [Na-(Cl-+HCo3)] to calculate anion gap. 
  The normal anion gap calculated in <12 2meq/L. 
  So the diagnosis of increased anion gap metabolic acidosis needs a 
anion gap of 10-12meq/L. 
  The severity of metabolic acidosis (blood ph, bicarbonate, 
ketones) and the presence of altered mental status are factors considered to 
classify the DKA into mild, moderate and severe (1). 
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  According to the blood ketone concentration there will be 
leukocytosis in patients with hyper glycemic emergencies (2, 10). In the 
presence of hyperglycemia, there will be shift of water from intracellular 
space to extracellular space, so the extracellular sodium on admission will be 
low. 
  But the profound water loss can lead to increased extra cellular 
sodium, so increased extracelluar fluid sodium may indicate profound 
dehydration. 
  If the plasma is not cleared of chylomicrons, Pseudo hyponatremia 
and pseudo normoglycemia can occur in hyperglycemic emergencies (37, 38). 
  Due to an extracellular shift of potassium caused by insulin 
deficiency, acidemia and hypertonicity and the serum potassium 
concentration can get elevated (3, 10, 39). 
  The treatment with insulin lowers the potassium, so in patients 
with low serum potassium concentration the insulin therapy can provoke 
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cardiac dysrhythmia. So these patients require intense cardiac monitoring, 
and they should be given potassium replacement adequately. 
  There is positive linear relationship between mental status change 
and serum osmolality, which is proven by studies on mental alteration and 
serum osmolality (14). 
  The presence of other causes of mental status changes should be 
considered, when patient presents with stupor or coma, but with no definite 
rise in serum osmolality (320 mosm/kg). 
  After the assessment of clinical features and laboratory features 
DKA can be classified into mild, moderate and severe types. 
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VARIABLES MILD MODERATE SEVERE 
Blood glucose mg/dl >250 >250 >250 
PH 7.25-7.3 7-7.24 <7 
HCo3
- 15-18 10-<15 <10 
Serum Ketone +ve +ve +ve 
Urine Ketone +ve +ve +ve 
Osmolality Variable Variable Variable 
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Anion Gap >10 >12 >12 
Mental Status Alert Drowsy Stupor or coma 
 
Differential Diagnosis 
  The clinical history and the plasma glucose concentrations that 
range from little elevated (rarely >200mg/dl) to even below normal, 
distinguishes the starvation ketoacidosis, alcoholic ketocidosis from diabetic 
ketoacidosis. So all patients with ketoacidosis may not be having DKA. 
  In starvation ketosis, the serum Bicarbonate concentration is not 
reduced to less than 18 meq/L usually, but in alcoholic ketoacidosis it is 
reduced.It can result in very severe metabolic acidosis. 
  High anion gap metabolic acidosis producing conditions like lactic 
acidosis, ingestion of drugs like salicylates, ethylene glycol, paraldehyde, 
methanol and chronic renal failure should be differentiated from DKA. 
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  DKA can be presenting manifestation of undiagnosed acromegaly. 
There are case reports showing this. (45, 48). 
 
 
Treatment of Diabetic Ketoacidosis: 
  Intra venous fluid replacement and Insulin therapy are the 
cornerstones in the treatment of DKA. After these, the precipitating factor 
should be identified as early as possible, and it should be treated promptly 
and aggressively. 
  A Ryle’s tube insertion should be done in all patients with 
complaints of vomiting and altered mental status, to prevent the aspiration 
induced pneumonitis. 
  Careful monitoring and periodic reassessment to confirm, that the 
patient is getting well and metabolic derangements are improving, are needed 
and it is central to successful treatment of DKA. 
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  Chronological changes in vital signs, fluid intake, output and 
laboratory values as a function of insulin administered should be recorded in a 
comprehensive flow sheet. 
  The first step in the management of DKA is to confirm the 
diagnosis by three laboratory parameters, plama glucose, positive serum 
ketones, metabolic acidosis. Then the patient must be admitted in hospital 
preferably in intensive-care setting if ph is less than 7, or if unconscious or if 
treatment monitoring is needed. Assessment of serum Na+, k+, mg2+, Cl, 
HCo3, Po4 and acid base status (ph, hco3, pco2, hydroxybutyrate), renal 
function (creatinine, urine output) should be done at frequent interval. The 
next step is replacement of fluids. 0.9% saline, 2-3 litres should be infused 
over 1-3 hours, followed by 250-500ml/hr infusion of 0.45% saline followed by 
150-250ml/hr infusion of 0.45% saline along with 5% glucose when the plasma 
glucose reaches concentration of 200mg/dl. 
  Next step in the management is, administration of short acting 
insulin that is 0.1 units/kg stat iv dose followed by 0.1 units/kg/hr iv infusion. 
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If there is no reponse by 2-4 hrs infusion rate can be increased to two or three 
fold. 
  Insulin therapy is not given when the initial plasma potassium is 
less than 3.3 meq/L. It can be started once the potassium is corrected. There 
is no supplementation of potassium is needed if the initial potassium is 
>5.2meq/L. until the potassium is corrected. Next step is the workup for 
precipitating factor, that is blood cultures, chest x ray, ECG to find what 
precipitated the event (non compliance, infection, trauma, infarction, 
cocaine). 
    Measurement of serum electrolytes (K+, HCO-3, Phosphate) and 
anion gap every 4 hours and measurement of capillary blood glucose every 1-
2 hr is mandatory in the management of DKA. 
  Blood pressure, pluse, respirations, mental status changes, fluid 
intake and urine output should be monitored every 1-4 hrly. 
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  When the ECG is normal, urine flow and creatinine are 
documented normal, potassium can be replaced. Potassium 10meq/hr can be 
infused if the serum K+ value is less than 5.2 meq/L. It can be increased upto 
40-80meq/hr when the serum k+ is less than 3.5meq/L. or if bicarbonate is 
given. 
  The goal is to achieve the concentration of glucose 150-250mg/dl. 
Until this, management should be continued then the insulin infusion may be 
decreased to 0.05-0.1 units/kg/per hour. 
  Once the patient started to eat, long acting insulin can be started. 
It is better to allow the overlap of insulin infusion and subcutaneous insulin 
injection. 
Complications: 
1. Hypokalemia and hypoglycemia because of insulin overdosage, are the 
most common complications. 
29 
 
2. 0.7-1.0% of children with DKA manifest themselves with cerebral edema 
frequently fatal but rare complication. It is common in newly diagnosed 
diabetes, particularly in children. The clinical features of cerebral edema 
are deterioration in the level of consciousness, decreased arousal, lethargy, 
headache, seizures maybe the presenting manifestations. The 
deterioration of neurological status is rapid. Incontinence, respiratory 
arrest, pupillary changes can accompany. These symptoms increases when 
the herniation of brain stem occurs. 
3. Hypoxemia 
4. Non cardiogenic pulmonary edema. 
  Both these can complicate the treatment of DKA. 
 
 
  Hypoxemia occurs due to the increased lung water content and 
decreased lung compliance attributed to the reduction in colloid osmotic 
pressure (10). 
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  Patients with DKA who is having crepitations on respiratory 
system auscultation and increased alveolo arteriolar oxygen gradient noted on 
initial blood gas measurement seem to be high risk for the development of 
pulmonary edema. 
 
5. Hyper chloremia 
6. ARDS 
7. Acute gastric dilatation 
8. Thrombo embolism 
9. Hyperglycemia 
10. Fluid overload 
 
 
 
Long term Management: 
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   Once the hyperglycemia is controlled, blood ketone reading is less 
than 1.0mmol/L, patient is eating well, and clinically stable, then the patient 
should be switched over to subcutaneous insulin therapy. 
   One hour after the first dose of subcutaneous insulin, intravenous 
infusion of insulin can be stopped. 
   Then the patient can be referred to specialized team of 
diabetologists for the further management. 
How to prevent DKA: 
   In newly diagnosed type 1 diabetes, education should be focused 
on raising the awareness of symptoms of hyperglycemia and also 
hypoglycemia in order to prevent DKA. 
   The metabolic derangements should be diagnosed earlier and 
prompty intervened to prevent the DKA in already established type 1 DM. 
   The development of glucose levels (>15mmol/L), may create a 
dilemma for patients and health care givers managing type 1 diabetes, because 
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of risk of developing DKA, even though the home monitoring of blood glucose 
is well established. 
   Patients can reduce the unnecessary hospital visits and more 
invasive tests by utilizing the point of contact testing facility by patients 
themselves and health care professionals. 
   Beta hydroxy butyrate will not raise more than 1mmol/litre 
in patients with type 1 diabetes, who do not have metabolic derangement. 
 
Better access to medical care, good communication with health care giver 
during episodes, and proper education can prevent many cases of DKA and 
HHS. Stoppage of insulin because of poor economic condition of family is one 
of the major cause of DKA in developing countries, insists the need of health 
care delivery system to look after this problem. Patient should be taught or 
how to manage themselves during illness, that is when to contact health care 
giver, ways to suppress infection and fever, use of supplemental rapid acting 
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insulin during illness and glucose goals and taking easily digestible liquid diet 
mainly of carbohydrate and salts. Patients should be advised to never 
discontinue insulin therapy. Family members should be taught how to 
measure blood glucose, monitoring of pulse, respiration, temperature, urine 
output and body weight. 
Serum Amylase  
  It is a heterogeneous calcium dependent metallo enzyme of M54-
62kDa. There are 2 iso enzymes exist: P type – Pancreatic, S-type-non 
Pancreatic. Highest activities of P-type enzyme is found in exocrine pancreas. 
S-type enzymes highest activities is being found in salivary glands. It has a very 
wide tissue distribution. Pancreatic acinar cells synthesize P-type amylase and 
secreted into the intestinal tract through the ductal system of pancreas. The 
mild alkaline condition of duodenum favours the action of P-type amylase. 
  The S-type amylase is synthesized in salivary glands, and it starts 
the hydrolysis of starch when the food is swallowed and passing through the 
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mouth and esophagus. The acid in the stomach terminates the action of S-
type amylase. 
  Extracts of testes, ovaries, fallopian tubes, mullerian ducts, 
striated muscle, lungs, adipose tissue, semen, colostrum, tears and milk are 
some of organs and secretions, where S-type amylase can be found. 
  Kidneys excrete about 25% of plasma amylase, but the majority of 
excreted amylase is reabsorbed by the proximal tubules  
 Macroamylasemia may complicate the measurement of serum 
amylase level. In macroamylasemia, the macro molecular complex that is 
made up of immunoglobulin and enzyme  is very large to be excreted by the 
kidneys. So the values may be falsely high. It leads to misdiagnosis of some 
abdominal conditions and erroneous treatment. 
  In acute pancreatitis some times serum amylase levels maybe 
normal because of the associated hyperlipedemia in this condition, for the 
reasons not known. 
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Hyper amylasemia causes: 
1.  Pancreatitis, Pancreatic trauma, pancreatic tumors etc, are some of the 
pancreatic diseases  showing elevated P-type amylase. 
2. Intra abdominal diseases: (eg) biliary treat diseases, obstruction, 
mesenteric infarction, liver disease, acute appendicitis – showing elevated 
P-type amylase 
3. Salivary gland infection, trauma, irradiation can cause raised S-type 
amylase. 
4. Tumoure of ovaries, prostate, testes, esophagus, thymus, thyroid, lung, 
ruptured ectopic pregnancy, and renal diseases including renal 
insufficiency can cause raised S-type amylase. 
5. HIV, DKA, macroamylasemia and various drugs (opiates, diuretics, steroids) 
are miscellaneous conditions causing elevation of serum amylase. 
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SERUM LIPASE 
  The triglycerides are hydrolysed by lipase. There are many forms 
of lipase available 
1. Pancreatic lipase 
2. Colipase 
3. Lipoprotein lipase 
  When there is decreased renal function, there will be elevated 
levels of coliapse, because coliapse is excreted by kidney. Lipoprotein lipase is 
essential in triglyceride hydrolysis, it is synthesized by vascular endothelium. 
CAUSES OF INCREASED LIPASE: 
Drugs:  lipase values are increased by corticosteroids. 
Acute pancreatitis: When pancreatic acinar tissue is destroyed, the pancreatic 
enzymes are released in to the pancreas and peritoneal cavity. 
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Gastrointestinal disease: lipase values are 2-3 times increased by peritonitis, 
bowel obstruction, visceral obstruction (laparotomy). Neoplasia and hepatic 
diseases. 
Decreased renal function: Decreased renal function can increase the lipase 
values upto 4 times the normal. When the lipase values are more than 3-4 
times, diagnosis of pancreatitis should be considered, even if the patient is 
azotemic (5). 
  There are studies reporting non specific hyper lipasemia in 
patients with DKA. Only few possible explanations can be offered to this 
finding. The molecular weight of lipase is 46-52KD is filtered in the kidneys to 
get reabsorbed by the renal tubules. In renal tubules the lipase gets 
metabolized. In DKA patients even with normal renal function the handling of 
lipase by the kidneys is compromised due to hypovolemia. So it may cause the 
elevation of serum lipase. 
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  When pancreatic beta cells are destroyed by immune mediated 
attack in type I DM, spillover causes the pancreatic acini to get damaged 
,thereby causing elevated serum lipase levels due to release in to the serum. 
 
 
Diabetic ketoacidosis – hyper amylasamia and hyperlipasemia: 
   In 16-25% of the time in DKA, increased amylase and lipase occurs 
(49) without actual pancreatic involvement. DKA can be precipitated by acute 
pancreatitis. Acute pancreatitis can present or co exist or aggravate its 
severity. (50) In DKA, there have been reports of elevated serum amylase (51). 
   7 Out 13 Patients with DKA had elevated concentrations of serum 
amylase found in one study (51). 
   Polyacrylamide gel electrophoresis prooved that 6 out 7 cases 
where salivary gland amylase not pancreatic amylase. So there is proof 
available that pancreas is not the source of elevated amylase usually. Systemic 
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derangement of carbohydrate metabolism in DKA can cause hyper amylasemia 
since salivary type amylase are widely distributed in glandular epithelium. The 
stomach and intestinal epithelium can release lipolytic enzymes in to the 
circulation in the presence DKA. When GFR is reduced due to the dehydration 
in DKA, it can lead to elevated serum lipase levels, without actual pancreatic 
involvement. 
  Hyper amylasemia has been reported very frequently in patients 
with DKA. Abdominal tenderness, vomiting, pain present in more than 50% of 
patients with DKA. Previously this findings were attributed to the diagnosis of 
acute pancreatitis. But recent studies proved that acute pancreatitis is rarely 
present in DKA, so that the abdominal symptoms and hyper amylasemia 
cannot be attributed to the presence of acute pancreatitis. 
  During episodes of DKA, hyper amylasemia develops during 
hospitalization, not in the initial phase of DKA. 
  The range of elevation of amylase level is variable in DKA. It ranges 
from mild elevation to six times the normal limit which is usually considered 
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specific for acute pancreatitis. But in DKA, the abdominal symptoms and 
hyperamylasemia has no correlation between them. The hyperamylasemia is 
present in both groups of patients with abdominal symptoms and without 
abdominal symptoms in equal frequency. 
  In majority of patients with DKA and hyper amylasemia it is 
proven that the elevated amylase is mainly salivary type of iso amylase not 
pancreatic iso amylase. Salivary iso amylase includes all forms of iso amylase 
except pancreatic iso amylase, so exact source of origin of iso amylase is not 
known. 
  Metabolic acidosis may cause elevated serum amylase. Studies 
showing that metabolic acidosis or respiratory acidosis in the absence of DKA 
or renal failure can cause elevated amylase levels. (56) But this relationship 
with metabolic acidosis and hyper amylasemia is not statistically significant. 
Some other studies showing the results of elevated serum amylase is salivary 
iso amylase from unknown source. 
DKA and Acute Pancreatitis 
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  There are two important associations between DKA and acute 
pancreatitis should be recognized 
1) In type II diabetes mellitus, there is increased incidence of gallstone 
formation because of obesity, so here acute pancreatitis can be triggered 
after the passage of gall stones. 
2) Type V hyperlipoproteinemia is associated with high risk for acute 
pancreatitis. In DM the patients usually have type IV hyper 
lipoproteinemia, in susceptible patients it can turn in to type IV hyper 
lipoproteinamia with increased fat intake. 
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MATERIALS AND METHODS 
SETTING 
  The study was conducted in the inpatients admitted in the Rajiv 
Gandhi Government general hospital Chennai 
STUDY DESIGN 
  Single Center 
  Cross Sectional Study 
STUDY PERIOD 
  Study was conducted between may 2012 and October 2012 for a 
period of 6 months. 
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SAMPLE SIZE 
   In the study period of 6 months, among the patients admitted in 
internal medicine ward after applying inclusion and exclusion criteria, 50 
patients were included in this study. 
   The patients who fulfilled the criteria for DKA were taken in to the 
study. 
Criteria for Diabetic keto acidosis: 
1. Hyper Glycemia ≥ 250 mg/dl 
2. Metabolic acidosis (Ph 6.3-7.3) and/or serum bicarbonate < 15 meq/L 
3. Ketonuria or ketonemia 
Inclusion Criteria 
1. Age: >18yrs 
2. Sex: Either Sex 
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3. DKA of any cause, both type I and type 2 DM 
 
Exclusion Criteria 
1. Patients with renal failure 
2. Chronic Alcoholics 
3. Patients with chronic Pancreatitis 
4. Patients with Pancreatic trauma 
5. Patients with Pancreatic tumours 
6. Patients with intestinal obstruction 
7. Patients with cholecystitis 
8. Patients with bowel perforation 
  Detailed clinical history was taken from all the patients who were 
included in the study. History of Symptoms of DKa and acute pancreatitis like 
polyuria, polydipsia, breathlessness, abdominal pain, abdominal distention, 
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nausea, vomiting, loose stool, fever, dysuria, myalgia, chest pain, mental 
disturbance  were elicited. 
  The past history including whether the patient was having type 1 
or type 2 diabetes mellitus, precipitation factors like omission of insulin 
elicited. Past history of hypertension, hyper lipidemia, jaundice, TB, epilepsy, 
CAD, CKD, CVA, thyroid abnormalities, were analyzed. Drug history, personal 
and family history all were elicited. 
  After taking the detailed history, all the patients were examined 
clinically in detail. A detailed general examination was done including, 
nourishment, pallor, fever, mental status changes, icterus, clubbing, pedal 
edema, significant lymphadenopathy, cyanosis. 
  Vital signs like pulse, blood pressure, temperature, respiratory 
rate were  taken. All the systems were examined carefully including optic 
fundus. 
  The following investigations were performed 
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1) Compete blood count – to find the anemia, leukocytosis, infections. 
2) Renal function tests- urea, creatinine, sodium, potassium, blood glucose. 
3) Liver function test – total bilirubin, Direct bilirubin, Alkaline phosphatase, 
transaminases, total protein, albumin, globulin. 
4) Chest Xray 
5) Electro cardiogram 
6) Urine routine- Albumin, sugar, deposits 
7) Urine acetone 
8) Serum calcium, phosphorous, magnesium, chloride 
9) Arterial ph 
10) Pa Co2 
11) Serum bicarbonate 
12) Urine culture & Sensitivity 
13) Serum osmolality calculation 
14) Serum lipid profile –Total cholesterol, Triglycerides etc. 
15) Serum Amylase and lipase estimation 
The normal values are  
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Serum amylase 20-96 U/L 
Serum lipase 3-43 U/L 
  In patients with DKA who shows the elevation of serum amylase 
and/or lipase, were done following imaging modalities to diagnose acute 
pancreatitis 
16) USG abdomen 
17) CECT abdomen. 
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RESULTS AND OBSERVATIONS 
  Among the 50 patients included in our study, 35 patients were 
males accounting for 70% of the total cases. The remaining 30% of the 
patients, that is 15 cases were females. 
 
 
   Distribution of sex in the study- figure-1. 
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Among the 50 cases of DKA, 10 cases (20%) belong to type-I DM. 
The remaining 40 cases (80%) belong to type II DM. 
 
 
Figure-2 Distribution of type of DM in the study. 
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  Among the 50 cases of DKA in our study, the precipitating factors 
that led to DKA were assessed. 
1. Omission of insulin-9 cases-(18%) 
2.CVA-13 cases (26%) 
3. Acute MI- 8 cases (16%) 
4. Infection- 11 cases (22%) 
5. No identitable cause- 9 cases (18%) 
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Omission of insulin 18.00% 
       CVA 26.00% 
       Acute MI 16.00% 
       Infection 22.00% 
       No identifiable cause 18.00% 
 
Figure-3. Distribution of precipitating causes of DKA in the study. 
  Among the 50 patients of DKA studied, 7 cases showed (14%) 
elevated serum amylase concentration. 
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  Then elevated serum amylase levels were divided into 2 groups. 
One group has less  than 3 times amylase elevation- in this group we had 3 
cases (6%) 
  Next group has more than or equal to 3 times (≥3 times) amylase 
concentration elevation. In this group we had 4 cases-(8%) 
  No of cases with elevated serum amylase concentration -7 (14%). 
Among these 7 cases 
1) <3times elevation – 3cases (6%). 
2) ≥3times elevation – 4 cases (8%) 
  Among the 50 patients of DKA studied, 14% of patients are 
showing elevation of serum amylase concentration. 
  But in those 14% cases were done USG abdomen and CECT 
abdomen to look for the evidences of acute pancreatitis. 
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  None of the cases showed any evidence of acute pancreatitis, 
even in cases with more than 3times elevation of serum amylase 
concentration, that is usually considered specific for acute pancreatitis 
  No of cases with raised serum amylase concentration – 7(14%) 
  No of cases which showed evidences of acute pancreatitis among 
this group - 0 
  Among the 50 patients of DKA studied, 11 cases (22%) showed 
elevated serum lipase concentration. 
  Then these cases were grouped into two. First group has Less than 
3 times elevation of serum lipase concentration. In this group we had 7 cases 
(14%). 
  Second group has patients with more than or equal to 3times 
(≥3times) elevation of serum lipase concentration. In this group we had 4 
cases (8%). 
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  No of cases with elevated serum lipase concentration-11 (22%) 
Among these 11 cases 
1) <3 times elevation – 7 cases (14%) 
2)≥3times elevation – 4 cases (8%) 
  No of cases which showed any evidences of acute pancreatitis in 
the groups - 0 
  All the cases who showed elevated serum lipase concentration 
were done USG abdomen and CECT abdomen 
  But none of them showed any evidences of Acute pancreatitis 
even in cases which showed more than 3 times elevation which is usually 
considered more specific for the diagnosis of acute pancreatitis. 
Finally it is concluded that 
1. No of cases with non specific elevation of serum amylase in DKA-7 (14%). 
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2.No of cases with non specific elevation of serum lipase concentration in DKA 
– 11(22%). 
  Among the 50 patients of DKA studied 2 cases were died. Those 
cases were having serum concentrations of amylase and lipase in normal 
range only. So there is no evidence for the increased mortality in patients with 
elevated serum amylase and lipase. 
  No of cases studied-50 
  No of cases died-2(4%) 
  Normal serum concentration of amylase and lipase were present 
in those 2 cases. 
  Among the 50 patients of DKA studied, there were 3kinds of 
results 
1. Normal 
2. Elevation of lipase concentration exclusively 
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3. Elevation of both serum amylase and lipase concentration. 
  The distribution of these results among various variables like Na+, 
K+, Hco3, urea, glucose, Type of DM, PH, osmolality were studied and any 
correlation between them were analysed. The results are following. 
1. TYPE OF DIABETES MELLITUS: 
No of cases 
Type of 
diabetes 
Normal 
range 
Lipase 
elevated 
Both Amylase + lipase 
elevated 
Total 
1. Type I 7 2 1 10 
2. Type II 32 2 6 40 
Total 39 4 7 50 
Table I – Distribution of amylase, lipase elevation among types of diabetes. 
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  Out of 10 cases of type-I DM 7 cases were showing normal results. 
Only 3 cases were showing elevation of (30%) enzymes concentration. (2 
cases – lipase only, 1 case both serum amylase + lipase elevated) 
  But in 40 cases of type2 DM, 32 cases were normal. 8 cases (20%) 
were showing abnormal results (2 cases- lipase only, 6 cases – both enzymes 
elevated). 
  Comparing these results, there is slightly increased number of 
cases were showing elevated serum concentration of amylase and lipase in 
type-I DM (30%) than type-2 DM (20%). But this is not statistically signifigant. 
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Figure-4 Distribution of serum amylase, lipase level among types of DM. 
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2. SERUM SODIUM 
Serum Na+ 
mmol/l. 
No of cases 
Normal Lipase 
elevation 
Amylase + 
lipase 
elevation 
Total 
1. <135 21 2 7 30 
2. 135-145 13 2 0 15 
3. >145 5 0 0 5 
Total 39 4 7 50 
 
Table-2 Distribution of serum amylase, lipase among various concentration of 
serum Na+. 
60 
 
  Among the 3 groups of serum Na+ Concentration, the first group, 
that is with serum Na+ concentration of <135mmol/L is showing more number 
of cases (30%) are showing combined elevation and exclusive lipase elevation 
than the 2nd group (135-145) which is showing 13.3% and 3rd (>145) group 
showing 0% only. 
 
Figure -5 Distribution of serum amylase and lipase among various serum Na+ 
concentrations. 
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3. SERUM POTASSIUM: 
Serum k+ 
mmol/l. 
No of cases 
Normal Lipase 
elevated 
Both 
Amylase + 
lipase 
elevated 
Total 
1) <3.5 0 0 1 1 
2) 3.5-5 13 0 2 15 
3) >5 26 4 4 34 
Total 39 4 7 50 
 
Table – 3 Distribution of serum amylase, lipase among, various concentrations 
of serum k+ 
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  Among the three group of various k+ concentration, only one case 
is distributed into concentration of <3.5 which is having elevation of both 
amylase & lipase (100%). 
  But in the second group (3.5-5 mmol/L) is showing 13% incidence 
of combined elevation and exclusive lipase elevation. 
In the 3rd group (>5 mmol/L) 23% of cases are showing combined elevation 
and exclusive lipase elevation. 
  So amylase and lipase concentrations were high in patients with 
low K+ and also high K+ serum concentrations. 
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Figure-6- Distrubtion of serum amylase and lipase among various k+ 
concentrations. 
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4. SERUM OSMOLALITY. 
Serum 
osmolality 
mosm/kg 
No of cases 
Normal Lipase Combined 
elevation 
Total 
1. 275-295 9 0 1 10 
2. >295 30 4 6 40 
Total 39 4 7 50 
 
Table-4 Distribution of serum amylase and lipase among different serum 
osmolality groups.) 
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  Among the two groups studied, the first group (serum osmalility 
275-295 mosm/kg) showed only 10% of cases have combined elevation and 
exclusive lipase elevation. But in the second group (>295 mosm/kg) 25% of 
cases showing combined elevation and exclusive lipase elevation. 
  So amylase and lipase concentrations were high in patients with 
increased osmolality 
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Figure-7 
Distribution of serum amylase, lipase among different serum osmolality 
groups. 
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5. ARTERIAL PH. 
Ph No of cases 
Normal Lipase Combined 
elevation 
Total 
1. <7 0 2 2 4 
2. 7-7.24 30 2 4 36 
3. 7.25-7.3 9 0 1 10 
Total 39 4 7 50 
Table-5 Distribution of serum amylase and lipase among different ph groups. 
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  Among the different Arterial ph groups studied, there is all the 
cases (100%) in group (ph<7) showing combined elevation and exclusive lipase 
elevation. 
  But in the 2nd group (ph 7-7.20) only 16.6% of cases showing 
combined elevation and exclusive lipase elevation. 
  In the 3rd group (ph 7.25-7.3) only 10% of cases are showing 
combined elevation and exclusive lipase elevation. 
  So it can be concluded that fall in Ph is associated with elevated 
serum amylase and lipase concentration. 
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Figure-8 Distribution of serum amylase and lipase among various arterial ph 
groups. 
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6. SERUM HCO3 
Srum Hco3 
meq/L 
No of cases 
Normal Lipase Both Total 
1.  Less than 10 1 1 1 3 
2. 10-15 35 3 6 44 
3. 15-18 3 0 0 3 
Total 39 4 7 50 
Table-6 Distribution of serum amylase and lipase among various serum Hco3 
groups. 
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  Among the 3 groups of serum Hco3 studied, the first group (serum 
Hco3 <10) is showing that 66% of cases are having combined elevation and 
exclusive lipase elevation. 
  But in the second group (serum Hco3 10-15) showing only 20% of 
cases are having combined elevation and exclusive lipase elevation. 
  In the 3rd group (serum Hco3 15-18) no patients are having 
elevation of serum amylase and lipase concentration. 
  So it can be concluded that low bicarbonate values are associated 
with increased serum amylase and lipase concentration. 
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Figure-9 Distribution of serum amylase and lipase among different 
bicarbonate groups. 
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7. PLASMA GLUCOSE. 
Blood glucose 
mgld1 
No of cases 
Normal Lipase Both Total 
1. lessthan 500 36 2 6 44 
2. more than  
≥500 
3 2 1 6 
Total 39 4 7 50 
Table-7 Distribution of serum amylase and lipase among different blood 
glucose groups. 
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  Among the two groups studied, there is increased incidence 
serum amylase and/or lipase concentration elevation in second group (blood 
glucose >,500mg/dl) that is 50% than the first group (18% only). 
 
Figure-10 Distribution of serum amylase and/or lipase among different plasma 
glucose groups. 
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8. BLOOD UREA. 
Blood urea 
mgldl 
No of cases 
Normal Lipase Both Total 
1. 40-60 20 2 1 23 
2. 61-80 19 1 3 23 
3. >80 0 1 3 4 
Total 39 4 7 50 
Table-8 Distribution of serum amylase and/or lipase among different blood 
urea groups 
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  Among the 3 groups studied, there is increased  (100%) serum 
amylase and/or lipase concentration elevation in patients with high blood 
urea (>80mg/dl) -3rd group than in the 2nd group (17.3%) and 1st group (13%). 
 
Figure-11 Distribution of serum amylase and/or lipase among different blood 
urea groups. 
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 Mean value of serum amylase in patients with blood urea 
<60mgldl is 63.45. Mean value of serum amylase in patients with blood urea ≥ 
60mg ldl is 115.56.  Pvalue. 0.0518 Considered not quite significient 
 Mean value of serum lipase in patients with blood urea <60mgldl 
is 46.45. Mean value of serum lipase in patients with blood urea > 60mgldl is 
52. The P. value is 0.65 This is statistically not significant. 
 Mean value of serum amylase in patients plasma glucose >500 
mgldl is 94.3 mean value of serum amylase in patients with ≤ 500mg ld is 92.5. 
The P value is 0.96. statistically not significant. 
  Mean value of serum lipase in patients with plasma glucose >500 
is 109.5. mean value of serum lipase in patients with plasma glucose ≤500 is 
41.86. The P value is 0.0008 This is considered extremely significant. 
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DISCUSSION 
  Various authors have studied the serum amylase and lipase 
enzyme abnormalities in the patients of DKA. But most of the studies were 
unable to prove any relationship between the raise of serum amylase and 
lipase concentration and actual pancreatic involvement, probably of non 
specific elevation. 
  M.C. Vantyghem et al (52) measured serum total amylase (TA), 
pancreatic amylase (PA) lipase (L) and leukocyte elastase’ in 4 groups of 
patients. 1st group consists of patients with DKA, 2nd group consists of 
patients with porly controlled non-ketotic DM. Third group patients are well 
controlled DM. Fourth group consists of Non DM persons. 
  The mean serum enzyme activities were significantly higher in 
group-1 than 2, 3, 4. In all the patients studied, the four enzymes have 
correlation between themselves and with glucose, BUN, HCO3
.In group-1 
the TA has negative correlation with serum HCO3 and arterial Ph. Pancreatic 
amylase and lipase correlated with BUN and glucose positively and also it 
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had negative correlation with HCO3 PA correlated with Ph positively. This 
study had a conclusion that raise of pancreatic enzymes correlated mainly 
with hyperglycemia, dehydration and acidosis 
  Vinicor F et al (53) concluded in his study that 79% of patients in 
DKA had hyper amylasemia with 48% are having pancreatic type amylase. 
Fontaine P et al (54) concluded that the hyper amylasemia is subclinical and 
can represent the effects of hyper tonicity (or) hypo perfusion. 
  Kitabchi et al (55) in his study concluded that lipase is a more 
sensitive and specific indicator of pancreatitis but it can also get elevated in 
DKA 
  Eckfeldt et al (56) collected serum from 33 patients with metabolic 
or respiratory acidosis in the absence of diabetic acidosis or renal failure. 
The total serum amylase was elevated in 36% of these patients and five 
patients had marked elevations in a range usually considered diagnostic of 
acute pancreatitis. 
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  Yadav D Nair et al (57) in their study, they evaluated 150 
consecutive episodes of DKA in 135 patients. They were evaluated for 
serum amylase, lipase and biochemical markers of DKA on admission and 24 
hours later. 
  Patients were divided into 3 groups according to the results, those 
were clearly non specific amylase elevation (<3 times), clearly non specific 
lipase elevation (<3 times). Probably non specific amylase or lipase 
elevation (>3 times). The results were, non specific amylase elevations in 
16.6% of cases (10% if cases were showing more than 3 times elevation, 
and 6.6% if cases were showing less than 3 times elevation). 
  Non specific lipase elevation is present in 24% of cases, out of 
which 15.3% of cases were showing less than 3 times elevation and 8.7% of 
cases were showing more than 3 times elevation. 
  They have concluded that non specific elevation of amylase and 
lipase present in 16-25% of cases. 
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  Amylase elevation is correlated with serum osmolality and ph, 
lipase elevation is correlated with serum osmolality alone. 
  Andrew L. Warshaw et al (58) found 7 out of 13 patients with DKA 
had raised concentration of serum amylase. Iso enzyme analysis confirmed 
that elevated amylase is salivary iso enzyme type not pancreatic type. They 
concluded that hyper amylasemia in DKA  is most often due to 
carbohydrate metabolic derangements. 
  Nair’s et al (59) observed 100 consecutive episodes of DKA during 
a period of 13 months. Careful history, CBC, ABG, Comprehensive metabolic 
assay, Serum amylase, lipase, and TG levels were estimated on admission 
and 48 hr later. 
  All patients with abdominal pain and elevated serum amylase and 
lipase levels were done CT abdomen to diagnose acute pancreatitis  
  They noted elevation of lipase in 29% and amylase in 21% of 
cases, without any CT evidence of acute pancreatitis 
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  They concluded that elevation of serum lipase and amylase occur 
in DKA, but lipase levels elevation seems to be less specific than amylase 
level elevation for the acute pancreatitis diagnosis 
  A.H. knight et al (60) analyzed 35 consecutive episodes of DKA 
showed the elevated serum amylase concentration frequently. 
  In 60% of cases, there were elevation of amylase out of which 17% 
showed very high levels. They found that the initial blood sugar value of 
more than 500mg/dl and acute (<48hrs) onset of episode correlated with 
hyper amylasemia. 
  There were no evidences of acute pancreatitis in these cases, and 
no other causes of hyper amylasemia found. There is no increased mortality 
and morbidity associated with hyper amylasemia. 
  D.N. Williams et al (61) presented a case of diabetic with reduced 
GFR who developed lactic acidosis and hyper amylasemia after treated with 
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phenformin. There is no evidences of acute pancreatitis in that case. The 
patient succumbed. 
  So it is concluded that hyper amylasemia can be present in 
patients with lactic acidosis without any evidence of acute pancreatitis. 
  Ali A Rizvi et al (62) reported 2 cases of DKA with non specific 
elevation of serum amylase and lipase. He concluded that both amylase and 
lipase can get elevated non specifically in the setting of DKA without any 
significance. So both hyper amylasemia and hyper lipasemia are not 
diagnostive of AP in the setting of DKA. 
  In our study, we had 14% of cases were showing elevated serum 
amylase concentration, out  of which 6% of cases were having less than 3 
times elevation and 8% of cases were having more than 3 times elevation. 
But none of the cases showed any evidence of acute pancreatitis. This 
results are consistent with studies of M.C. vantyghem et al, Vincor F. et al, 
Yadav D. Nair et al, Andrew L. Warshaw et al, Nair S. et al, A.H. Knight et al, 
and Ali A. Rizvi et al. 
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  In our study, we had 22% of cases were showing elevated serum 
lipase concentration. Out of which 14% of cases were having less than 3 
times elevation and 8% of cases were having more than 3 times elevation. 
But no cases had any evidence of acute pancreatitis. All cases were having 
non specific elevation probably. This results are consistent with the studies 
of M.C. Vantyghem et al, kitabchi et al, Yadav D. Nair et al, Nairs et al, and 
Ali A. Rizvi et al. 
  Out study showed, that non specific lipase elevation present in 
more number of cases (22%) than non specific amylase elevation (14%). So 
lipase levels elevation seems to be less specific than amylase level elevation 
for the diagnosis of acute pancreatitis. This result is consistent with the 
results of Nair S. et al and Yadav D. Nair et al. 
  In our study, there is no increase in the mortality rate among the 
cases with elevation of serum amylase and/or lipase concentration. This is 
consistent with the studies of A.H. Knight et al. 
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  In our study serum amylase and/or lipase concentration were 
elevated in those cases with high serum osmolality (>295 mosm/kg). This is 
consistent with studies of M.C. Vantyghem et al, Fontaine P. et al, Yadav D. 
Nair et al. 
  In our study, serum amylase and/or lipase concentration were 
elevated in those patients with arterial ph of less than 7. This is consistent 
with studies of M.C. Vantyghem et al, Eckfeldt et al, Yadav D. Nair et al, and 
D.N. Williams et al. 
  In our study serum amylase and/or lipase concentration were 
elevated in patients with serum bicarbonate of less than 10 meg/L. This is 
consistent with the results of M. C. Vantyghem et al. 
  In our study serum amylase and/or lipase concentration were 
elevated more in cases with high plasma glucose (>500 mg/dl). This is 
consistent with the studies of M. C. Vantyghem et al, and Andrew L. 
Warshaw et al. 
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  In our study serum amylase and/or lipase concentration were 
elevated more in patients with high blood urea (>80mg/dl). This is 
consistent with studies of M. C. Vantyghem et al and D. N. Williams et al. 
 
 
 
 
 
 
 
 
 
 
87 
 
CONCLUSIONS 
1. Elevation of serum amylase and lipase concentration occur in patients of 
DKA 
2. 14% of cases with DKA are showing non specific elevation of serum 
amylase with no evidences of acute pancreatitis 
3. 22% of cases with DKA are showing non specific elevation of serum 
lipase with no evidences of AP 
4. Even more then 3times elevation of serum amylase and or lipase is not 
associated with AP 
5. Among the precipitating causes of DKA, CVA leads, followed by 
infections, omission of insulin, myocardial infarction and no identifiable 
cause. 
6. There is no increased mortality attributable  to increased serum amylase 
and/or lipase concentration 
7. There is increased serum amylase and/or lipase concentration in type I 
DM (30%) than type 2DM (20%) 
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8. There is increased serum amylase and/or lipase concentration in 
patients with decreased serum Na+ concentration (<135 mmol/L). 
9. There is increased serum amylase and/or lipase concentration in 
patients with both low k+ (<3.5mmol/L) and high K+ (>5mmol/L) 
concentrations. 
10. There is increased serum amylase and/or lipase concentration in 
patients with high osmolality of serum (>295mosm/kg) 
11. There is increased serum amylase and/or lipase concentration in 
patients with low arterial ph < 7 
12. There is increased serum amylase and/or lipase concentration in 
patients with low serum bicarbonate (<10 meq/L) 
13. There is increased serum amylase and/or lipase concentration in 
patients with high blood urea conentration (>80mg/d1) 
14. There is increased serum amylase and/or lipase concentration in 
patients with high blood glucose (>500mg/dl) concentration.  
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15. Serum lipase concentration is elevated more in patients with plasma 
glucose of >500mg/dl, which is considered statistically extremely 
significant (p value0.0008) 
16. There increased serum amylase and/or lipase concentration in patients 
with DKA in probably due to metabolic derangements not due to acute 
pancreatitis. 
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 ABBREVATIONS 
DM – Diabetic Mellitus 
DKA – Diabetic Keto Acidosis 
AP – Acute Pancreatitis 
TA – Total Amylase 
PA – Pancreatic Amylase 
SA – Salivary Amylase 
L – Lipase 
GFR – Glomerular Filtration Rate 
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                                          PROFORMA 
Elevated serum amylase and lipase levels without actual 
pancreatic involvement in the presence of diabetic ketoacidosis - 
an observational study 
 
NAME: AGE/SEX: 
IP NO: WEIGHT: 
DOA: HEIGHT: 
COMPLAINTS: Yes/No 
Polyuria 
Polydipsia 
Breathlesness 
Abd-pain 
Abd. distension 
Vomiting 
Nausea 
Loose stool 
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Fever 
Dysuria 
Myalgia 
Others 
Past H/o. DM - Type I/II   Yes/No 
Inadequate insulin (or) withdrawal of  Administration 
HT 
Drugs 
Jaundice 
TB 
Epilepsy 
CAD 
CKD 
CVA 
Hypo/Hyper Thyroid 
Pancreatic Ca/ Tumour 
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Cholescystitis 
Panereatitis 
Personal H/O: 
Alcoholic 
Smoker 
Family H/o.: 
Occupational H/o: 
Menstrual & Obst. H/o: 
General Examination     Yes/No 
Consciousness 
Orientation 
Pallor 
Icterus 
Clubbing 
Cyanosis 
Pedal Edema 
Lymph Node enlargement 
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Dehydration - Mild/Moderate/Severe 
Vital Signs: 
PR 
BP 
RR 
Temperature 
JVP 
Systemic Examination 
CVS 
RS 
Abdomen 
CNS 
Investigations: 
HB gm/dl 
Tc cells/cu.mm 
DC P%L% E% 
ESR 
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Urea mg/dl 
Creatinine mg/dl 
Sugar mg/dl 
Na+ meq/L 
K+ meq/L 
Ca++ meq/dl 
PO4
3– meq/dl 
Mg 
Cl– 
Arterial pH 
PaCO2  
Serum HCO3 
Urine Examination: 
Albumin 
Sugar 
Acetone 
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Deposits 
Urine C&S 
Liver Function Tests: 
T.Protein 
Albumin 
Glubulin 
Serum Lipid Profile: 
Total Cholesterol 
Triglyceride 
12 lead ECG 
Chest x-ray 
USG abdomen 
Serum Amylase 
Serum Lipase 
CT. Abdemen 
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S.No Name Age Sex IP.NO Type of diabetes Precipit factor Urea Creatinine Sugar Na K
Serum 
osmalarity PH PaCO2
Serum 
HCO3 Amylase Lipse
1 Maheswari 44 Female 42813 Type2 Omission 92 1.5 520 124 5.9 303 6.9 21 8 280 118
2 Saranya 20 Female 43257 Type1 No cause 58 1.2 512 134 6.1 328 6.9 28 11 52 252
3 Rajamanikam 60 Male 43590 Type2 SHT/CAD/NSTEMI 55 1.4 312 131 5.3 299 7.25 29 10 140 96
4 Karpagam 60 Female 45320 Type2 CAD/NSTEMI 59 1.1 389 136 5.4 314 7 32 14 80 128
5 Shanmugam 73 Male 48329 Type2
Inadequate 
insulin/CAD/NSTE
MI
88 1.3 431 132 3.8 310 6.9 22 10 482 54
6 Stephan 19 Male 48374 Type2 Omission of insulin 72 1.2 412 124 3.1 289 7.1 21 12 104 150
7 Suresh nandha sharma 60 Male 50567 Type2 Omission 82 1.3 451 132 5.2 312 7.2 29 14 382 49
8 Appavoo 48 Male 50709 Type2 No cause 64 1.2 356 132 5.1 304 7.2 29 14 82 92
9 Vanjinathan 45 Male 50807 Type2 Omission 71 1.2 511 131 5.2 312 7.2 2.8 14 72 32
10 Girija 40 Female 52068 Type2 UTI 69 1.3 431 141 5.4 328 7.27 24 10 95 42
11 Shantha kumari 60 Female 52117 Type2 CVA 64 1.3 432 142 5.3 328 7.24 22 12 95 42
12 Periyasamy 18 Male 53139 Type2 New case 71 1.6 451 134 5.4 316 7.2 26 13 95 42
13 Perumal 70 Male 53219 Type1 CVA 56 1.2 451 126 3.9 294 7.25 29 13 95 42
14 Kumaresan 17 Male 53333 Type1 New case 54 1.4 512 138 5.2 323 7.25 25 15 95 42
15 kuppamma 45 Female 54598 Type2 Pneumonia 54 1.3 356 134 5.5 307 7.28 28 14 95 42
16 Jaya 56 Female 54729 Type2 Pneumonia 64 1.4 454 142 5.7 330 7.14 21 14 95 42
17 Kolanji 53 Male 55721 Type2 CVA 63 1.3 382 134 3.8 308 7.29 29 14 95 42
18 Moorthi 52 Male 55887 Type2 CVA 62 1.3 392 128 3.8 295 7.3 22 14 95 42
19 Badrakali 73 Female 59953 Type2 CVA 51 1.3 424 145 5.4 332 7.21 24 14 95 42
20 Revathy 50 Female 61649 Type2 UTI 69 1.4 456 144 4.8 333 7.19 20 13 95 42
21 Radhakrishnan 63 Male 62806 Type2 NSTEMI 61 1.2 430 132 5.1 308 7.2 27 14 32 36
22 Venugopal 54 Male 63603 Type2 NSTEMI 54 1.2 412 132 5.2 306 7.2 26 13 70 32
23 Deveudran 60 Male 64573 Type2 Omission 59 1.2 356 138 5.6 316 7.2 26 14 95 42
24 Aruldoss 70 Male 65183 Type2 AGE 52 1.2 413 131 5.1 304 7.2 29 14 95 42
25 Alimohamed 50 Male 65488 Type2 CVA 59 1.4 412 124 3.6 287 7.2 28 14 95 42
26 Suresh 45 Male 67985 Type2 UTI 64 1.5 434 148 5.4 341 7.18 24 14 95 42
27 Santharam 54 Male 68005 Type2 CVA 56 1.3 464 140 4 322 7.2 25 12 95 42
28 Kalyani 48 Female 69200 Type2 Pneumonia 61 1.3 389 148 5.4 338 7.24 21 12 95 42
29 Elisebath 77 Female 71337 Type2 CVA 54 1.3 392 151 5.6 343 7.2 21 12 95 42
30 Devraj 43 Male 71879 Type2 Acute MI 51 1.1 312 132 5.4 300 7.1825 22 13 95 42
31 Kumeresan 17 Male 72273 Type1 Omission 78 1.1 380 128 3.9 298 7.2 28 13 356 59
32 Kumaresan 17 Male 72378 Type1 New case 81 1.3 513 135 5.8 323 6.8 21 7 49 198
33 Rajarathnam 65 Male 72410 Type2 Age 68 1.4 456 132 5.6 311 7.1825 22 14 95 42
34 Abirami 13 Female 72758 Type1 Omission 54 1.2 350 135 5.5 309 7.2 21 12 95 42
35 Shakira begam 65 Female 73947 Type2 UTI 64 1.5 346 146 5.5 332 7.2 24 14 95 42
36 Ragu 46 Male 74745 Type2 Acute MI 49 1.2 321 130 5.1 295 7.25 27 14 95 42
37 Anandhan 50 Male 75115 Type2 CVA 56 1.4 391 143 5 322 7.2 27 13 95 42
38 Gurunathan 62 Male 75238 Type2 CVA 61 1.3 346 121 5 281.2 7.21 28 15 95 42
39 Anbalagan 61 Male 75727 Type2 CVA 59 1.3 399 134 4.9 354 7.27 21 13 95 42
40 Kanniammal 65 Female 76320 Type2 CVA 64 1.4 431 148 5.6 341 7.2 22 14 95 42
41 Kavipriya 20 Female 76393 Type1 New case 59 1.3 356 140 5.4 320 7.23 22 12 95 42
42 Abdul majid 52 Male 77445 Type2 Pneumonia 59 1.2 404 122 4.8 286 7.21 25 12 95 42
43 Velu 38 Male 79883 Type2 Pneumonia 72 1.5 386 126 5 295 7.2 24 13 95 42
44 Rajeshwaran 14 Male 80015 Type1 New case 70 1.6 505 126 5.1 301 7.2 21 12 95 42
45 Yuvarai 15 Male 82326 Type1 New case 59 1.4 456 142 5 329 7.2 24 13 95 42
46 Ravi 50 Male 82783 Type2 Omission 60 1.2 382 130 5.2 301 7.2 26 13 95 42
47 Kaliyamoorthy 65 Male 84314 Type2 Pneumonia 52 1.4 290 128 5.1 290 7.3 2.4 13 95 42
48 Nitin Jose 21 Male 84399 Type1 New case 62 1.3 434 124 3.8 290 7.2 22 15 95 42
49 Panner selavam 52 Male 84692 Type2 Inadequate Insulin 62 1.3 456 138 5.4 321 7.2 26 12 95 42
50 Poosanam 64 Male 142905 Type2 Acute MI 63 1.2 430 131 5.1 306 7.2 26 13 302 152
